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OBJECTIVES: The objective of the study was to evalu-
ate the short-term costs and cost-effectiveness of initiat-
ing therapy with an angiotensin II receptor antagonist
compared to a calcium channel blocker in type II diabetic
patients with microalbuminuria. METHODS: An eco-
nomic model was developed based upon a multicenter,
randomized, double-blind, 24-week trial comparing the
angiotensin II receptor antagonist valsartan (n = 169)
with the calcium channel blocker amlodipine (n = 163) in
Type 2 diabetic patients with microalbuminuria. The
primary outcome measure was urinary albumin excretion
rate (UAER) and the secondary outcome measure was the
return to normoalbuminuric status. Resource use was col-
lected through study administration reports, adverse
event reports and concurrent medication reports. Costs
were applied to resources at German speciﬁc payment
rates for services and medications (EBM, GOÄ 2002 etc.).
RESULTS: Changes in UAER were 44.2% with valsartan
and 8.2% with amlodipine (p < 0.01). Changes in albu-
minuric status were 29.9% with valsartan and 15.5%
with amlodipine (p < 0.01). Blood pressure was equally
controlled with both medications. HbA1c remained
stable and did not differ between treatments. With costs
expressed in EUR (€), total costs were €638.18 with val-
sartan and €503.66 with amlodipine. Incremental cost-
effectiveness ratios were 374 for changes in UAER and
874 for changes in albuminuric status. CONCLUSIONS:
Use of valsartan compared to amlodipine in diabetics
with microalbuminuria was associated with signiﬁcantly
improved UAER and albuminuric status at similar total
treatment costs. The combination of signiﬁcantly higher
efﬁcacy and higher costs yields incremental cost-
effectiveness ratios that are favorable for the use of val-
sartan over amlodipine.
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OBJECTIVE: The ability to perceive vibration (vibration
detection) has been shown to be a good predictor of long-
term complications among patients with diabetic periph-
eral neuropathy (DPN). The aim of the study was to esti-
mate the predicted complications and costs for the NHS
associated with reduced vibration detection. METHODS:
A Markov model of DPN progression was constructed
for a hypothetical cohort of people with DPN. The model
was run over a 10-year period using Monte Carlo simu-
lations to estimate disease progression, predicted costs,
life-years and quality-adjusted life-years (QALYs) accord-
ing to vibration detection levels. Rates of foot ulceration
and amputation, the probability of healing, and health
state utility scores were identiﬁed by undertaking a
focused literature search. The cost data used in the model
were derived from a concurrent cost of illness study.
RESULTS: Discounted over ten-years, the average indi-
vidual with reduced vibration detection incurs approxi-
mately 3.3 times more direct medical costs for foot ulcers
and amputations (£1531 vs. £457), yields 0.19 fewer
QALYs, and lives for approximately 2 months shorter
than an average individual with normal vibration detec-
tion. The long-term complications of DPN (foot ulcers
and amputations) experienced by the population with
reduced vibration detection will cost the NHS approxi-
mately £292m (discounted) over the next 10 years. CON-
CLUSIONS: Effective treatment of foot ulceration and
amputation is time-consuming and expensive. If at-risk
individuals with reduced vibration detection could be
identiﬁed and targeted for intervention, valuable Health
care resources could be saved and improved health out-
comes should result. For example, if all individuals in the
UK with diabetes and reduced vibration detection were
identiﬁed and their risk of ulceration and amputation
reduced to levels experienced by those with normal vibra-
tion detection, this could save the NHS up to £204m, and
save 29,000 life-years and 36,000 QALYs (discounted)
over the next ten years.
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OBJECTIVES: The Cost Of Diabetes type 2 in Poland
(CODIP) study is the ﬁrst attempt aimed at valuating clin-
ical characteristics and total costs associated with type 2
diabetes in Poland. Study design reﬂects that of CODE 2
(Cost Of Diabetes in Europe type2) and allows for inter-
national comparison. METHODS: Three hundred-three
patients randomly enrolled, (mean age: 61, mean time
from diagnosis: 10.86 year, males: 49%) were divided
into 4 categories: no complications, one or more micro-
vascular complications, one or more macrovascular 
complications, one or more of each microvascular and
macrovascular complications. Direct cost associated with
